Eliquis Dosage
Generic name: apixaban 2.5mg
Dosage form: tablet, film coated
Drug class: Factor Xa inhibitors
Medically reviewed by Drugs.com. Last updated on Apr 17, 2025.
Recommended Dose in Adult Patients
Reduction of Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation
The recommended dose of ELIQUIS for most patients is 5 mg taken orally twice daily.
The recommended dose of ELIQUIS is 2.5 mg twice daily in patients with at least two of the following characteristics:
- •
- age greater than or equal to 80 years
- •
- body weight less than or equal to 60 kg
- •
- serum creatinine greater than or equal to 1.5 mg/dL
Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery
The recommended dose of ELIQUIS is 2.5 mg taken orally twice daily. The initial dose should be taken 12 to 24 hours after surgery.
- •
- In patients undergoing hip replacement surgery, the recommended duration of treatment is 35 days.
- •
- In patients undergoing knee replacement surgery, the recommended duration of treatment is 12 days.
2.2 Recommended Dose in Pediatric Patients
Treatment of Venous Thromboembolism (VTE) and Reduction in the Risk of Recurrent VTE in Pediatric Patients
The recommended dose of ELIQUIS is based on the patient’s weight, see Table 1. Adjust the dose according to weight-tier as treatment progresses. Initiate ELIQUIS treatment for pediatric patients from birth to less than 18 years of age following at least 5 days of initial anticoagulation therapy. Individualize duration of overall therapy after careful assessment of the treatment benefit and the risk for bleeding.
Table 1: Dose Recommendation in Pediatric Patients from Birth to less than 18 Years of Age for the Treatment of VTE and Reduction in the Risk of Recurrent VTE
Days 1-7 |
Days 8 and beyond |
||
Presentation |
Body weight (kg) |
Dosing schedule |
Dosing schedule |
Powder in Capsule 0.15 mg For pediatric use |
2.6 to less than 4 |
0.3 mg twice daily |
0.15 mg twice daily |
Tablet 0.5 mg For pediatric use |
4 to less than 6 |
1 mg twice daily |
0.5 mg twice daily |
6 to less than 9 |
2 mg twice daily |
1 mg twice daily |
|
9 to less than 12 |
3 mg twice daily |
1.5 mg twice daily |
|
12 to less than 18 |
4 mg twice daily |
2 mg twice daily |
|
18 to less than 25 |
6 mg twice daily |
3 mg twice daily |
|
25 to less than 35 |
8 mg twice daily |
4 mg twice daily |
|
Tablets 2.5 mg and 5 mg |
greater than or equal to 35 |
10 mg twice daily |
5 mg twice daily |
ELIQUIS is not recommended for use in pediatric patients less than 2.6 kg because ELIQUIS was not studied in these patients.
Missed Dose
If a dose of ELIQUIS is not taken at the scheduled time, the dose should be taken as soon as possible on the same day and twice-daily administration should be resumed. The dose should not be doubled to make up for a missed dose.
Temporary Interruption for Surgery and Other Interventions
ELIQUIS should be discontinued at least 48 hours prior to elective surgery or invasive procedures with a moderate or high risk of unacceptable or clinically significant bleeding. ELIQUIS should be discontinued at least 24 hours prior to elective surgery or invasive procedures with a low risk of bleeding or where the bleeding would be non-critical in location and easily controlled. Bridging anticoagulation during the 24 to 48 hours after stopping ELIQUIS and prior to the intervention is not generally required. ELIQUIS should be restarted after the surgical or other procedures as soon as adequate hemostasis has been established.
Converting from or to ELIQUIS
Switching from warfarin to ELIQUIS: Warfarin should be discontinued and ELIQUIS started when the international normalized ratio (INR) is below 2.0.
Switching from ELIQUIS to warfarin: ELIQUIS affects INR, so that initial INR measurements during the transition to warfarin may not be useful for determining the appropriate dose of warfarin. One approach is to discontinue ELIQUIS and begin both a parenteral anticoagulant and warfarin at the time the next dose of ELIQUIS would have been taken, discontinuing the parenteral anticoagulant when INR reaches an acceptable range.
Switching from ELIQUIS to anticoagulants other than warfarin (oral or parenteral): Discontinue ELIQUIS and begin taking the new anticoagulant other than warfarin at the usual time of the next dose of ELIQUIS.
Switching from anticoagulants other than warfarin (oral or parenteral) to ELIQUIS: Discontinue the anticoagulant other than warfarin and begin taking ELIQUIS at the usual time of the next dose of the anticoagulant other than warfarin.
Combined P-gp and Strong CYP3A4 Inhibitors
For adult patients receiving ELIQUIS doses of 5 mg or 10 mg twice daily, reduce the dose by 50% when ELIQUIS is coadministered with drugs that are combined P-glycoprotein (P-gp) and strong cytochrome P450 3A4 (CYP3A4) inhibitors (e.g., ketoconazole, itraconazole, ritonavir).
In patients already taking 2.5 mg twice daily, avoid coadministration of ELIQUIS with combined P-gp and strong CYP3A4 inhibitors.
Administration Options
Adult and pediatric patients weighing greater than or equal to 35 kg.
For patients who are unable to swallow whole tablets, 5 mg and 2.5 mg ELIQUIS tablets may be crushed and suspended in water, 5% dextrose in water (D5W), or apple juice, or mixed with applesauce and promptly administered orally. Alternatively, ELIQUIS tablets may be crushed and suspended in 60 mL of water or D5W and promptly delivered through a 12 French nasogastric tube.
Following administration of the dose, the nasogastric tube should be flushed with an additional 20 mL of water or D5W.
Crushed ELIQUIS tablets are stable in water, D5W, apple juice, and applesauce for up to 4 hours.
Pediatric patients weighing less than 35 kg.
Capsules
The 0.15 mg ELIQUIS SPRINKLE capsule must be opened, and the entire contents sprinkled in water or infant formula, mixed, and administered as described in the Instructions for Use (IFU). The liquid mixtures should be administered within 2 hours. Do not swallow capsule.
Tablets for oral suspension
The 0.5 mg ELIQUIS tablet in a packet for oral suspension should be mixed with water, infant formula, apple juice, or apple sauce as described in the IFU. The liquid mixtures with water, infant formula or apple juice should be administered within 2 hours and the mixture in apple sauce should be administered immediately. Each packet is for single use only. For pediatric patients who have difficulty swallowing, the liquid mixture can be delivered through a 5 French, 6.5 French or 12 French nasogastric tube or gastrostomy tube. See IFU.
Frequently asked questions
- What foods should I avoid while on Eliquis?
- Top 6 Eliquis Side Effects: What You Need to Know in Depth
- Xarelto vs Eliquis: How do they compare?
- How do I stop and start Eliquis for surgery?
- Switching from Eliquis to Xarelto: What do I need to know?
- How do you reverse bleeding with Xarelto?
- Does Feverfew interact with any drugs?
- What are biologic drugs and how do they work?
More about Eliquis (apixaban)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (241)
- Drug images
- Side effects
- Patient tips
- During pregnancy
- Generic availability
- Support group
- FDA approval history
- Drug class: factor Xa inhibitors
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
See also:
Xarelto
Xarelto (rivaroxaban) is a factor Xa inhibitor used to reduce the risk of blood clots and stroke in ...
Lovenox
Lovenox is used to prevent deep vein thrombosis (DVT) which can lead to blood clots in the lungs ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Coumadin
Coumadin is used to prevent heart attacks, strokes, and blood clots in veins and arteries. Learn ...
Brilinta
Brilinta (ticagrelor) is used to lower your risk of having a stroke or serious heart problems after ...
Rivaroxaban
Rivaroxaban systemic is used for atrial fibrillation, cardiovascular risk reduction, congenital ...
Heparin
Heparin injection is used to treat and prevent blood clots in the veins, arteries, or lungs. Learn ...
Enoxaparin
Enoxaparin systemic is used for acute coronary syndrome, angina, deep vein thrombosis, deep vein ...
Pradaxa
Pradaxa (dabigatran) is used to prevent stroke and blood clots in patients with atrial ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.